Ciprofibrate diminishes NON-HDLc and improves HDLc in patients with Frederickson type IV dyslipidemia phenotype

Objective: Hypertriacylglyceridemia and low HDLc combination is one of the most common lipidic abnormalities. Thus, the aim of this study was to determine the effects of Ciprofibrate on patients with Frederickson’s Type IV dyslipidemia phenotype. Research design and methods: 75 patients with type IV dyslipidemia were assigned at random to one of two therapeutic options: Group A, AHA diet and physical activity and B, AHA diet, physical activity and Ciprofibrate 100 mg daily for 12 weeks. All patients underwent lipidic profile quantification before and after therapeutic intervention. Results: Ciprofibrate treatment group exhibited significantly reduction in total cholesterol (-14,2% vs. -4,8%; p<0,02), triglycerides (-38% vs. -21,6%; p<0,007), VLDLc (-38% vs. -21,6%; p<0,007) Non-HDLc (-20,5% vs. -7,1%; p<0,007) and total cholesterol to HDLc ratio (-25,6% vs. -9,4%; p<0,01) when comparing with diet/physical activity group . HDLc showed an important increase in Ciprofibrate group when contrast with diet/physical activity group (+25% vs. +9,6%, p<0,02). Conclusions: Ciprofibrate treatment effectively reduced triglycerides rich particles and Non-HDLc and significantly increased HDLc, proving it’s usefulness in low HDLc syndrome and type IV Frederickson’s hyperlipidemia.

Bibliographic Details

Main Authors:	Bermúdez-Pirela,V, Souki,A, Cano-Ponce,C, Bermúdez-Arias,F, Mengual-Moreno,E, Leal-Gonzalez,E, Lemus-Antepaz,M, Cabrera de B,M, Amell de D,A, Leal de P,N, Cano-Peñaloza,R, Puche-Medina,G, Ramirez,I, Contreras,F, Velasco,M
Format:	Digital revista
Language:	English
Published:	Sociedad Venezolana de Farmacológia y Farmacológia Clínica y Terapéutica. Escuela de Medicina 2005
Online Access:	http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S0798-02642005000200003
Tags:	Add Tag No Tags, Be the first to tag this record!